morpholine;(Z)-4-oxo-4-[(2-phenylimidazo[2,1-b][1,3]thiazol-6-yl)methoxy]but-2-enoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: morpholine;(Z)-4-oxo-4-[(2-phenylimidazo[2,1-b][1,3]thiazol-6-yl)methoxy]but-2-enoic acid
• 化学式: C20H21N3O5S
• 分子量: 415.5
• InChiKey: IWXXLBCJRFVBIC-NAFXZHHSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.35
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  130
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments
  申请人：Laboratorios del. Dr. Esteve, S.A.

  公开号：EP2682395A1

  公开（公告）日：2014-01-08

  The present invention relates to imidazo[2,1-b]thiazole derivatives (I) having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.

  本发明涉及具有对σ受体，特别是σ-1受体具有很高亲和力的咪唑并[2,1-b]噻唑衍生物(I)，以及其制备方法、包含它们的组合物和作为药物的用途。
• [EN] IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS<br/>[FR] DÉRIVÉS D'IMADAZO[2,1-B]THIAZOLE, LEUR PRÉPARATION ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS
  申请人：ESTEVE LABOR DR

  公开号：WO2014006130A1

  公开（公告）日：2014-01-09

  The present invention relates to new imidazo[2,1-b]thiazole derivatives (I) having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.

  本发明涉及具有对西格玛受体，尤其是西格玛-1受体具有很强亲和力的新咪唑[2,1-b]噻唑衍生物（I），以及其制备方法、包含它们的组合物，以及它们作为药物的用途。
• IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS
  申请人：LABORATORIOS DEL DR. ESTEVE S.A.

  公开号：US20150166574A1

  公开（公告）日：2015-06-18

  The present invention relates to new imidazo[2,1-b]thiazole derivatives having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.

  本发明涉及新的咪唑[2,1-b]噻唑衍生物，具有对sigma受体，特别是sigma-1受体的高亲和力，以及其制备过程，包括它们的组合物和用作药物的用途。
• US9617281B2
  申请人：——

  公开号：US9617281B2

  公开（公告）日：2017-04-11